Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eton Pharmaceuticals filings document a rare-disease pharmaceutical business built around approved products, licensed commercialization rights and late-stage product candidates. Recent 8-K reports cover DESMODA FDA approval for central diabetes insipidus, the HEMANGEOL U.S. rights acquisition and launch, ET-700 clinical study disclosure for Wilson disease, and quarterly and annual financial results that include GAAP and non-GAAP measures.
The filing record also includes credit-agreement amendments, direct financial obligation disclosures, executive appointment and compensation matters, and definitive proxy materials covering executive compensation, equity awards and governance matters. These filings tie product portfolio changes, financing terms, capital structure and corporate governance to Eton's public-company reporting.
Eton Pharmaceuticals (NASDAQ:ETON) filed an 8-K to disclose that the company will be added to the Russell 3000 and Russell 2000 indexes effective after the U.S. market close on June 27 2025.
The filing, made under Item 8.01, includes a press release (Exhibit 99.1) and signals broader passive fund ownership, higher trading liquidity and increased institutional visibility. No financial results, strategic shifts or governance changes were reported.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose an auditor transition effective 13 June 2025.
Dismissal of Crowe LLP: The Audit Committee terminated Crowe LLP after only one audit cycle (FY-2024). Crowe’s 2024 opinion was clean (no adverse or qualified opinion), and the firm reported no disagreements or reportable events with management under Item 304(a)(1) of Regulation S-K. Crowe’s required concurrence letter is attached as Exhibit 16.1.
Appointment of Grant Thornton LLP: The Audit Committee simultaneously engaged Grant Thornton LLP as the new independent registered public accounting firm for FY-2025. The company confirms that, during FY-2023, FY-2024, and the subsequent interim period, it did not consult Grant Thornton on any accounting matters or potential opinions prior to the appointment.
Investor takeaways:
- The change appears procedural; the absence of disagreements reduces immediate red-flag risk.
- Auditor turnover after one year may still prompt investors to monitor governance continuity and upcoming audit fees or timelines.
- No financial restatements, outlook changes, or earnings data were disclosed in this filing.